Flash Finance

Orchid Pharma LimitedORCHPHARMACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹911.25
MCap ₹4,622 Cr · P/E 101.3
Orchid Pharma Limited — Stock analysis & AI research Orchid Pharma Limited — Multibagger AI analysis Orchid Pharma Limited — Seasonality — best & worst months Orchid Pharma Limited — Technical indicators & charts Orchid Pharma Limited — Technical setup — score, trend, support & resistance Orchid Pharma Limited — Live exchange announcements
📋 Promoters Increasing Stake📋 High Promoter Holding Stocks 📈 SuperTrend Bearish Signal📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹238 Cr
Sales · Mar 2026
+0.2% YoY
₹29 Cr
Operating Profit · Mar 2026
-15.5% YoY
12.2%
OPM % · Mar 2026
-15.9% YoY
₹31 Cr
Net Profit · Mar 2026
+11.3% YoY
₹6.03
EPS · Mar 2026
+9.8% YoY

📝 Orchid Pharma Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Orchid Pharma Limited reported revenue of ₹238 crore for the quarter ended March 2026 (Q4 FY26), up 0.2% from ₹237 crore in the same quarter last year, and up 14.8% sequentially over the December 2025 quarter.

Net profit rose 11.3% year-on-year to ₹31 crore, from ₹28 crore. Earnings per share (EPS) came in at ₹6.03.

Operating profit stood at ₹29 crore — an operating margin (OPM) of 12.2%, compared with 14.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Orchid Pharma Limited posted revenue of ₹812 crore, a decline of 11.9% over FY25, with a net profit of ₹46 crore (down 57.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹812 crore with a net profit of ₹46 crore.

Valuation snapshot

At the current price of ₹911.25, ORCHPHARMA has a market capitalisation of ₹4,622 crore and a trailing P/E of about 101.3.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 11th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Aug 2026, promoters held 74.45%, foreign institutional investors (FIIs) 0.93%, domestic institutional investors (DIIs) 17.54%, public shareholders 7.08% of Orchid Pharma Limited.

Promoter holding rose from 69.84% to 74.45% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,622 Cr
Current Price ?
₹911.2
P/E ?
101.35above ind
Industry P/E ?
37.20
P/B ?
3.37
P/S ?
5.69
P/FCF ?
-121.63
Enterprise Value ?
₹4,807 Cr
EV/EBITDA ?
106.01
PEG ?
1.88
Earnings Yield ?
0.2%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹812 Cr
OPM ?
5.6%
Profit after tax (TTM) ?
₹46 Cr
EPS (TTM) ?
₹8.99
ROCE ?
4.0%
ROE ?
3.3%
ROA ?
2.6%
Growth
Sales — latest qtr ?
₹238 Cr
PAT — latest qtr ?
₹31 Cr
YoY qtr sales growth ?
0.2%
YoY qtr profit growth ?
11.3%
Sales growth (3y) ?
7%
Sales growth (5y) ?
12%
Profit growth (3y) ?
54%
Profit growth (5y) ?
20%
Financial Health
Debt ?
₹185 Cr
Debt to Equity ?
0.14
Interest Coverage ?
0.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
74.45%
Change in promoter holding ?
4.61%
Pledged percentage ?
N/A
Market
Return 3 months ?
-12.5%
Return 6 months ?
60.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 160210183199221217244223217237173194207238 +0.2% +14.8%
Operating Profit 1440222436293330263414-1329 -15.5% +922.8%
Other Income 940287138810616151114 +123.8% +32.2%
Interest 87644333443433 -24.6% -5.3%
Depreciation 87889889999999 +2.7% +0.4%
Profit Before Tax 7651120313029262428182-631 +11.3% +632.3%
Net Profit 7651120313329262428182-631 +11.3% +632.3%
EPS —15.892.644.406.026.545.745.054.715.493.590.44-1.156.03 +9.8% +624.3%
OPM % 8.5% 19.0% 12.1% 11.9% 16.3% 13.3% 13.6% 13.3% 12.0% 14.5% 8.2% -0.3% 1.4% 12.2% -15.9% +771.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹922 Cr ₹812 Cr ₹812 Cr -11.9%
Operating Profit ₹123 Cr ₹45 Cr ₹45 Cr -63.2%
OPM % 13.36% 5.59% 5.59% -58.2%
NPM % 11.56% 5.62% 5.62% -51.4%
Other Income ₹32 Cr ₹56 Cr ₹56 Cr +74.9%
Depreciation ₹35 Cr ₹35 Cr ₹35 Cr +1.7%
Interest ₹15 Cr ₹13 Cr ₹13 Cr -10.8%
EBIT ₹88 Cr ₹10 Cr ₹10 Cr -88.8%
PBT ₹107 Cr ₹46 Cr ₹46 Cr -57.2%
Tax — — — —
Net Profit ₹107 Cr ₹46 Cr ₹46 Cr -57.2%
EPS ₹20.99 ₹8.91 ₹8.91 -57.6%
Material Cost ₹445 Cr ₹343 Cr ₹343 Cr -23.0%
Employee Cost ₹64 Cr ₹69 Cr ₹69 Cr +6.6%
Extraordinary Items — ₹-7 Cr ₹-7 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 41515151 +0.0%
Reserves 6911,1681,2731,319 +3.6%
Borrowings 331135175185 +5.7%
Other Liabilities 160199198195 -1.5%
Total Liabilities 1,2231,5521,6971,750 +3.1%
Fixed Assets 573616613670 +9.3%
CWIP 46244495 +115.9%
Investments 506969256 +271.0%
Other Assets 554842970729 -24.8%
Total Assets 1,2231,5521,6971,750 +3.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1313127119 +340.7%
Cash from Investing Activity -27-316-37-125 -237.8%
Cash from Financing Activity 3116725-8 -132.0%
Net Cash Flow 18-1816-15 -193.8%
Free Cash Flow -1376-41-38 +7.3%
CFO/OP 16%117%23%256% +1013.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1168496119 +24.0%
Inventory Days 217199219178 -18.7%
Days Payable 130135114111 -2.6%
Cash Conversion Cycle 204148200186 -7.0%
Working Capital Days 79140152174 +14.5%
ROCE % 5%9%9%4% -55.6%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Aug 2026 % Chg
Promoters 69.84%69.84%69.84%69.84%69.84%74.45% +6.6%
FIIs 1.39%1.56%1.17%0.87%0.81%0.93% +14.8%
DIIs 19.43%19.04%19.38%20.24%20.75%17.54% -15.5%
Public 9.34%9.57%9.61%9.04%8.61%7.08% -17.8%
No. of Shareholders 39,82738,15535,70935,11833,43333,260 -0.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Orchid Pharma Limited's revenue in Q4 FY26?
Orchid Pharma Limited reported revenue of ₹238 crore for the quarter ended March 2026 (Q4 FY26), up 0.2% from ₹237 crore in the same quarter last year, and up 14.8% sequentially over the December 2025 quarter.
What was Orchid Pharma Limited's net profit in Q4 FY26?
Net profit rose 11.3% year-on-year to ₹31 crore, from ₹28 crore. Earnings per share (EPS) came in at ₹6.03.
What is ORCHPHARMA's market capitalisation and P/E ratio?
At the current price of ₹911.25, ORCHPHARMA has a market capitalisation of ₹4,622 crore and a trailing P/E of about 101.3.
Who owns Orchid Pharma Limited? (shareholding pattern)
As of Aug 2026, promoters held 74.45%, foreign institutional investors (FIIs) 0.93%, domestic institutional investors (DIIs) 17.54%, public shareholders 7.08% of Orchid Pharma Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI